Unduh Oncology Nursing Drug Handbook - v3.5.13

Anda pernah mendengar tentang Oncology Nursing Drug Handbook - v3.5.13, atau iDentist Dental practice management, Medical PG, FMGE Preparation - PrepLadder, NYP, Medical Dictionary Free & Offline - Diseases, Jan Aushadhi Sugam (BPPI), X-RAY WOW, salah satu Aplikasi paling keren di kategori Kedokteran.

Dan tentu saja Anda tahu bahwa, tidak semua game atau aplikasi kompatibel untuk semua ponsel. Game atau aplikasi terkadang tidak tersedia di perangkat Anda, itu tergantung pada versi sistem. Sistem operasi Android, resolusi layar, atau negara yang diizinkan aksesnya oleh Google Play. Itulah sebabnya APKPanda menyediakan file APK Android untuk Anda unduh dan tidak mematuhi batasan ini.>
Oncology Nursing Drug Handbook - v3.5.13 versi terbaru adalah 3.5.13, tanggal rilis 2020-06-25, dan memiliki ukuran 8.4 MB.Dikembangkan oleh Skyscape Medpresso Inc, Oncology Nursing Drug Handbook - v3.5.13 memerlukan versi Android setidaknya Android 5.0+. Oleh karena itu, Anda harus memperbarui ponsel Anda jika perlu.

Cukup banyak dimuat, tentang 1000 unduhan. Anda dapat memperbarui aplikasi yang telah diunduh atau dipasang satu per satu pada perangkat Android Anda jika Anda mau. Memperbarui aplikasi memberi Anda izin akses ke fitur-fitur terbaru dan meningkatkan keamanan dan stabilitas aplikasi.

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity